Adalta

Adalta P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Adalta (1AD.AX) as of Nov 5, 2026 is -2.01. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -3.04 — a change of -33.86% (higher).

P/CF

-2.01

YoY

-33.86%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Adalta is 2026 -2.01 . P/CF (Price-to-Cash-Flow Ratio) of Adalta was 2025 -3.04 . It decreases by -33.86% higher compared to the previous year.

The Adalta P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2019
-1.53 AUD
Jan 1, 2020
-1.52 AUD
Jan 1, 2021
-1.87 AUD
Jan 1, 2022
-2.18 AUD
Jan 1, 2023
-1.74 AUD
Jan 1, 2024
-1.70 AUD
Jan 1, 2025
-3.04 AUD
Jan 1, 2026
-2.01 AUD
The Adalta P/CF history
YEARP/CFYoY
-2.01-33.86%
-3.04+79.12%
-1.70-2.43%
-1.74-20.33%
-2.18+16.95%
-1.87+23.16%
-1.52-1.24%
-1.53-32.45%
-2.27-5.14%
-2.39-68.49%
-7.60+17.72%
-6.46-6.68%
-6.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Adalta Stock analysis

What does Adalta do? AdAlta Ltd. operates as a biotechnology company that discovers, develops, and commercializes protein based therapeutics. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies. Adalta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adalta stock

P/CF (Price-to-Cash-Flow Ratio) of Adalta is -2.01 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of Adalta changed from -3.04 to -2.01, representing a -33.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Adalta since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Adalta with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Adalta

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Adalta